Stock Research for SNY

Featured Broker: Ally Invest

Get the due diligence for another stock.


SNY Stock Chart & Research Data

The SNY chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the SNY chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


SNY Due diligence Resources & Stock Charts

The SNY stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View SNY Detailed Price Forecast - CNN Money CNN View SNY Detailed Summary - Google Finance
Yahoo View SNY Detailed Summary - Yahoo! Finance Zacks View SNY Stock Research & Analysis -

Stock Analysis

TradeIdeas View SNY Trends & Analysis - Trade-Ideas Barrons View SNY Major Holders - Barrons
NASDAQ View SNY Call Transcripts - NASDAQ Seeking View SNY Breaking News & Analysis - Seeking Alpha
Spotlight View SNY Annual Report - OTC Report View SNY OTC Short Report -
TradeKing View SNY Fundamentals - TradeKing Charts View SNY SEC Filings - Bar Chart
WSJ View Historical Prices for SNY - The WSJ Morningstar View Performance/Total Return for SNY - Morningstar
MarketWatch View the Analyst Estimates for SNY - MarketWatch CNBC View the Earnings History for SNY - CNBC
StockMarketWatch View the SNY Earnings - StockMarketWatch MacroAxis View SNY Buy or Sell Recommendations - MacroAxis
Bullish View the SNY Bullish Patterns - American Bulls Short Pains View SNY Short Pain Metrics -

Social Media Mentions

StockTwits View SNY Stock Mentions - StockTwits PennyStocks View SNY Stock Mentions - PennyStockTweets
Twitter View SNY Stock Mentions - Twitter Invest Hub View SNY Investment Forum News - Investor Hub
Yahoo View SNY Stock Mentions - Yahoo! Message Board Seeking Alpha View SNY Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for SNY - Insider Cow View Insider Transactions for SNY - Insider Cow
CNBC View SNY Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for SNY - OTC Markets
Yahoo View Insider Transactions for SNY - Yahoo! Finance NASDAQ View Institutional Holdings for SNY - NASDAQ

Stock Charts

FinViz View SNY Stock Insight & Charts - StockCharts View SNY Investment Charts -
BarChart View SNY Stock Overview & Charts - BarChart Trading View View SNY User Generated Charts - Trading View

Latest Financial News for SNY

Benzinga's Daily Biotech Pulse: AbbVie Files sNDA For Leukemia Drug, AcelRx Offering, Aurinia Starts Mid-Stage Trial
Posted on Thursday July 12, 2018

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 11) AC Immune SA (NASDAQ: ACIU ) Arbutus Biopharma Corp (NASDAQ: ...

BofA Revives Myokardia With New Buy Rating
Posted on Tuesday July 10, 2018

Myokardia Inc (NASDAQ: MYOK ) stock is up 290 percent year-over-year, but upcoming stimulants could drive additional outperformance, according to Bank of America Merrill Lynch.  The Analyst BofA's  Tazeen ...

Sanofi denounces CADTH negative recommendation that could limit treatment options for Canadians with atopic dermatitis
Posted on Tuesday July 10, 2018

LAVAL, QC , July 10, 2018 /CNW Telbec/ - Sanofi Genzyme is disappointed with the recent recommendation by the Canadian Agency for Drugs and Technologies in Health (CADTH) to not reimburse Dupixent™, one of the most important recent pharmacological innovations for the treatment of adult patients with moderate-to-severe atopic dermatitis (AD). This recommendation disregards patient input and ignores the product's clinical value and the potential improvement to patient and caregiver quality-of-life (QoL). In 2017, Health Canada, the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approved Dupixent™ based on its clinical value and benefits to patients with moderate-to-severe AD.

French government monitoring Sanofi plant at centre of pollution complaint
Posted on Monday July 09, 2018

The French government said on Tuesday that it was monitoring the situation at Sanofi's Mourenx plant in southwestern France to ensure the drugmaker had taken steps against pollution problems before it would allow the plant to re-open. Sanofi said on Monday that it had stopped production at the plant after an environment body filed a complaint against what it said was massive air pollution. France Nature Environnement, a federation representing some 3,500 local associations, said emissions at the Mourenx plant, which produces the epilepsy treatment valproate, had been 7,000 times above the limit allowed by French law.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.